TP53 and non-small cell lung carcinoma: Among the chemotherapy options available without targeting the p53 effect, the cytotoxic agent irinotecan (CPT-11), a semisynthetic analog of camptothecin, has been used for NSCLC chemotherapy [1,3,4,6,7].